To the Editor,

The main objectives of antiretroviral therapy (ART) are to suppress virus replication, preserve and improve immunological functions, and reduce human immunodeficiency virus (HIV)-related morbidity and mortality. In phase 3 ART-related studies, results of patients with baseline viral load of \>100,000 c/mL were reported ([@ref1],[@ref2],[@ref3]), whereas data with ≥1 million c/mL in real-life study are limited. Here, we represented virological and immunological responses in patients with HIV-1 infection who had a virological load of \>1 million copies and received ART with an integrase inhibitor (INI) combination.

We evaluated a single-center, retrospective study of HIV-infected adult patients who had a virological load of \>1 million copies followed in our Clinic of Infectious Diseases, between 2015 and 2018. HIV-RNA value \<50 c/mL at week 24 was defined as virological success. The increase in the number of CD + T lymphocyte count 50-100 cells/mm^3^ in the first year is considered as an immunological success.

A total of 16 patients were enrolled. The mean age of patients was 40 (range of 18-73) years; 93.8% of the patients were men. Eleven patients were on a single tablet regimen; 5 on elvitegravir (EVG), cobicistat, emtricitabine (FTC), and tenofovir alafenamide; 3 on EVG, c, FTC, and tenofovir disoproxil fumarate; 3 on dolutegravir, abacavir, and lamivudine; and 5 on multi-tablet therapy. The mean viral load of the patients was 4,467,618 (1,025,032-10,000,000) c/mL. The virological response of the patients to the treatment at 4^th^, 24^th^, and 48^th^ weeks are shown in [Figure 1](#f1){ref-type="fig"}. The immunological response was detected in 87.5% (14 patients) at 24^th^ and 94% (15 patients) at 48^th^ week. None of the seven responders at the 24^th^ week used additional medications. Three of the nine patients who did not respond at 24^th^ week were receiving other medical treatments for their comorbidities. Of the 7 responders at 24^th^ week, only one received a multi-tablet regimen, whereas 4 out of 9 unresponsive patients at 24^th^ week were receiving multi-tablet therapy. Age, the number of comorbidities, and the use of multi-tablet regimens were higher in those who did not experience virological response at 24^th^ week.

In a study of Santoro et al. ([@ref4]), 1,430 treatment-naive cases were divided into three groups according to viremia levels (≤30,000, 30,001--500,000, and \>500,000 c/mL) and evaluated for virologic response to treatment. The lowest virological success rate at 48 weeks was observed in the group with viral load \>500,000 c/mL. They stated that the revision of the frequently used 100,000 threshold value can be considered.

Sax et al. ([@ref5]) wrote a letter on 41 treatment-naive cases with pretreatment virological load ≥1 million c/mL in phase 3 clinical trials. They found that the rate of virological success (HIV-RNA \<50 c/mL) was 33% at 12^th^ week, 67% at 24^th^ week, and 97% at 48^th^ week. Similar to this study, our cases had lower virological response rates at 24^th^ week compared that at 48^th^ week.

Although the low number of patients in our study is the most important limitation, INI combination regimens were found to be very successful in patients with viral load \>1 million c/mL. However, reasons such as comedicating or taking the drug in a single tablet or multiple tablets form may cause some disruptions in compliance and delays in virological response. In this context, we believe that the 24-week period for virological failure in the guidelines can be kept more flexible for these cases.
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